AstraZeneca Pharma India Limited (ASTRAZEN) Financial History

Name: AstraZeneca Pharma India Limited (ASTRAZEN) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-09-20

AstraZeneca Pharma India Limited (ASTRAZEN) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Bengaluru, India with about 600 employees. Its market capitalization is roughly ₹169 billion. In the fiscal year ended 2026-03-31, ASTRAZEN reported ₹22.7B in revenue and ₹1.9B in net income.

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally.

Interactive charts & full statements →

ASTRAZEN Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Revenue	₹22.7B	₹17.1B	₹13.0B	₹10.0B
Gross Profit	₹7.8B	₹7.1B	₹6.2B	₹5.8B
Operating Income (EBIT)	₹2.3B	₹2.1B	₹1.7B	₹1.5B
Net Income	₹1.9B	₹1.2B	₹1.6B	₹993M

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ASTRAZEN Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31
Total Revenue	₹6.8B	₹5.8B	₹6.1B	₹5.6B	₹5.3B	—	—
Gross Profit	₹2.4B	₹1.8B	₹2.5B	₹2.3B	₹2.3B	—	—
Operating Income (EBIT)	₹437M	₹553M	₹410M	₹726M	₹645M	—	—
Net Income	₹379M	₹449M	₹326M	₹542M	₹558M	—	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ASTRAZEN Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Dividends Paid	(₹800M)	(₹600M)	(₹400M)	(₹200M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ASTRAZEN Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹19.9B	₹15.2B	₹10.8B	₹9.8B	—
Total Liabilities	₹11.2B	₹7.5B	₹3.7B	₹4.0B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ASTRAZEN viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

4887 · Sawai Group Holdings Co., Ltd. — JPY 189 billion
ERIS · Eris Lifesciences Limited — ₹183 billion
4553 · Towa Pharmaceutical Co., Ltd. — JPY 183 billion
ALIVUS · Alivus Life Sciences Limited — ₹176 billion
JUBLPHARMA · Jubilant Pharmova Limited — ₹169 billion
4547 · Kissei Pharmaceutical Co., Ltd. — JPY 168 billion
COHANCE · Cohance Lifesciences Limited — ₹168 billion
APLLTD · Alembic Pharmaceuticals Limited — ₹166 billion

← ASTRAMICRO All “A” companies ASTS →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.